NASDAQ · ALEC
Alector, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ALEC: Nov 5, 2026
Alector, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.23. The reported EPS for the same quarter last year was $-0.34.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.23 | $-0.22 | $-0.24 | 4 |
| Dec 2026 | $0.29 | $0.62 | $-0.26 | 3 |
| Mar 2027 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Jun 2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · MarketBeat · RTTNews- Zacks · Oct 30, 9:00 AM EDTEarnings Preview: Moderna (MRNA) Q3 Earnings Expected to DeclineModerna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 29, 9:00 AM EDTWill Alector (ALEC) Report Negative Q3 Earnings? What You Should KnowAlector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Fintel · Oct 23, 1:42 AM EDTAlector Consensus Price Target Increased by 25.81% to $3.98The average one-year price target for Alector (NASDAQGS:ALEC) (DB:0Z2) has been revised to $3.98 / share, up 25.81% from the prior mean of $3.16 dated September 29, 2026. These figures are aggregate analyst targets compiled by Fintel and do not constitute a recommendation by Fint
- MarketBeat · Oct 13, 3:02 PM EDTAlector Maps Brain-Delivery Pipeline for Alzheimer’s, Parkinson’s TherapiesThese biotechs targeting multiple neurodegenerative diseasesAlector (NASDAQ:ALEC) outlined its strategy to advance brain-penetrant therapies for neurodegenerative diseases, highlighting an anti-amyloid beta antibody for Alzheimer’s disease and two siRNA programs targeting tau and
- RTTNews · Oct 5, 7:32 AM EDTAlector Signs Global License Deal With Genentech For AL050(RTTNews) – Alector Inc. (ALEC), a biopharmaceutical company, on Monday announced that it has entered into an exclusive global licensing agreement with Genentech for its AL050 program.
- RTTNews · Sep 17, 5:00 AM EDTNovartis Halts Development Of VHB937 After ASTRALS Phase 2 Trial Fails To Meet Endpoint(RTTNews) – Novartis (NVS) announced on August 25, 2026, that its ASTRALS Phase 2 clinical trial evaluating VHB937 for amyotrophic lateral sclerosis did not meet its primary or secondary endpoints, leading the company to discontinue development of the investigational therapy.
- Zacks · Aug 6, 7:10 PM EDTAlector (ALEC) Reports Q2 Loss, Tops Revenue EstimatesAlector (ALEC) delivered earnings and revenue surprises of +12.50% and +283.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jun 30, 1:44 AM EDTRani Therapeutics Appoints Nicholas Maestas CFO Following Sanford Departure(RTTNews) – Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company, announced the appointment of Nicholas Maestas as Chief Financial Officer, effective immediately. He succeeds Svai Sanford, who announced his departure in May 2026 to pursue professional
- Zacks · May 7, 7:05 PM EDTAlector (ALEC) Reports Q1 Loss, Lags Revenue EstimatesAlector (ALEC) delivered earnings and revenue surprises of +40.00% and -65.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 7, 10:00 AM EDTWill Alector (ALEC) Report Negative Q1 Earnings? What You Should KnowAlector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · May 5, 8:25 AM EDTAlkermes (ALKS) Reports Q1 Loss, Beats Revenue EstimatesAlkermes (ALKS) delivered earnings and revenue surprises of +30.31% and +9.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Apr 15, 8:56 AM EDTCantor Fitzgerald Upgrades Alector (ALEC)Fintel reports that on April 15, 2026, Cantor Fitzgerald upgraded their outlook for Alector (NasdaqGS:ALEC) from Neutral to Overweight. Analyst Price Forecast Suggests 21.89% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Alector, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.